<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203187</url>
  </required_header>
  <id_info>
    <org_study_id>894860</org_study_id>
    <nct_id>NCT03203187</nct_id>
  </id_info>
  <brief_title>The Effect of Daily Mango Intake on Cardiovascular Health</brief_title>
  <official_title>The Effect of Daily Mango Intake (Mangifera Indica L.) on Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current proposal the investigators seek to evaluate the acute and short-term effects&#xD;
      of mango intake on vascular and platelet function in postmenopausal women between 50 and 70&#xD;
      years old.&#xD;
&#xD;
      Our aims are 1) to determine if two weeks of daily mango intake will result in favorable&#xD;
      changes in measures of vascular function, as measured using peripheral arterial tonometry&#xD;
      (PAT) and platelet reactivity, in overweight and obese postmenopausal women. 2) to determine&#xD;
      if two weeks of daily mango intake will change the fermentation capacity of gut microbiota.&#xD;
&#xD;
      Investigators hypothesize that the daily intake of 330 grams of mango (2 cups) will&#xD;
      significantly increase PAT while reducing platelet aggregation after 2 hours and two weeks of&#xD;
      daily intake.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2016</start_date>
  <completion_date type="Anticipated">August 14, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute vascular function</measure>
    <time_frame>change from baseline to 2 hours compared on days 0 14 and 28</time_frame>
    <description>Comparison of the effect of mango on acute vascular function between baseline and 2-hour postprandial response using PAT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term vascular function</measure>
    <time_frame>Comparison of day 0, 14, and 28</time_frame>
    <description>The effect of mango on long-term vascular function between baseline, two week, and four week time points using PAT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute platelet aggregation</measure>
    <time_frame>change from baseline to 2 hours compared on days 0 14 and 28</time_frame>
    <description>Comparison of the effect of mango on acute platelet aggregation between baseline and 2-hour postprandial time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term platelet aggregation</measure>
    <time_frame>Comparison of day 0, 14, and 28</time_frame>
    <description>Comparison of the effect of mango on long-term platelet aggregation baseline, two week, and four week time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>No mango intake</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No mango intake for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>330 grams of daily mango intake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>330 grams (2 cups) of daily mango intake for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mango</intervention_name>
    <description>330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening</description>
    <arm_group_label>330 grams of daily mango intake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No mango intake for two weeks.</description>
    <arm_group_label>No mango intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal female: 50-70 years&#xD;
&#xD;
          -  Women: lack of menses for at least one year and FSH 23-116.3 mlU/mL&#xD;
&#xD;
          -  Subject is willing and able to comply with the study protocols.&#xD;
&#xD;
          -  Subject is willing participate in all study procedures&#xD;
&#xD;
          -  BMI 25.0 - 40 kg/m2&#xD;
&#xD;
          -  Weight ≥ 110 pounds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 40 kg/m2&#xD;
&#xD;
          -  Dislike or allergy for mango&#xD;
&#xD;
          -  Self-reported use of daily anticoagulation agents including aspirin, NSAIDs&#xD;
&#xD;
          -  Vegan, Vegetarians, food faddists or those consuming a non-traditional diet&#xD;
&#xD;
          -  Alcohol consumption &gt; 3 drinks/week (i.e. 1 bottle of beer, ½ glass of wine, and 1&#xD;
             shot of hard liquor)&#xD;
&#xD;
          -  Fruit consumption ≥ 2 cups/day&#xD;
&#xD;
          -  Vegetable consumption ≥ 3 cups/day for females&#xD;
&#xD;
          -  Fatty Fish ≥ 3 times/week&#xD;
&#xD;
          -  Coffee/tea ≥ 3 cups/day&#xD;
&#xD;
          -  Dark chocolate ≥ 3 oz/day&#xD;
&#xD;
          -  Self-reported restriction of physical activity due to a chronic health condition&#xD;
&#xD;
          -  Self-reported chronic/routine high intensity exercise&#xD;
&#xD;
          -  Self-reported diabetes&#xD;
&#xD;
          -  Blood pressure ≥ 140/90 mm Hg&#xD;
&#xD;
          -  Self-reported renal or liver disease&#xD;
&#xD;
          -  Self-reported heart disease, which includes cardiovascular events and Stroke&#xD;
&#xD;
          -  Inability to properly place or wear the PAT probes or abnormal measurements on&#xD;
             pre-screening PAT&#xD;
&#xD;
          -  Abnormal Liver, CBC or Chemistry panels (laboratory values outside the reference&#xD;
             range) if determined to be clinically significant by the study physician.&#xD;
&#xD;
          -  Self-reported cancer within past 5 years&#xD;
&#xD;
          -  Self-reported malabsorption&#xD;
&#xD;
          -  Currently taking prescription drugs or supplements, other than thyroid medication.&#xD;
&#xD;
          -  Use of multi-vitamin and mineral other than a general formula of vitamins and minerals&#xD;
             that meet the RDA&#xD;
&#xD;
          -  Not willing to stop any supplement use, including herbal, plant or botanical, fish&#xD;
             oil, oil supplements a month prior to study enrollment.&#xD;
&#xD;
          -  Indications of substance or alcohol abuse within the last 3 years&#xD;
&#xD;
          -  Screening LDL ≥ 190 mg/dl for those who have 0-1 major risk factors apart from LDL&#xD;
             cholesterol (i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL].&#xD;
&#xD;
          -  Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL&#xD;
             cholesterol [i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL].&#xD;
&#xD;
        (using NCEP calculator http://cvdrisk.nhlbi.nih.gov/calculator.asp);&#xD;
&#xD;
          -  Screening LDL ≥ 130 mg/dl for those who have 2 major risk factors apart from LDL&#xD;
             cholesterol [i.e. family history of premature coronary artery disease (male first&#xD;
             degree relative &lt; 55 years; CHD in female first degree relative &lt; 65 years), cigarette&#xD;
             smoker, HDL-C ≤ 40 mg/dL], and a Framingham 10-year Risk Score 10-20% (using NCEP&#xD;
             calculator http://cvdrisk.nhlbi.nih.gov/calculator.asp).&#xD;
&#xD;
          -  Current enrollee in a clinical research study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Hackman, PhD</last_name>
    <phone>5309790417</phone>
    <email>rmhackman@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regal Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Li</last_name>
      <phone>530-761-8971</phone>
      <email>xxlli@ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

